Underrepresentation in clinical trials is an issue that not only deprives patients of access to potentially life-saving treatment, but it also widens the care gap for future generations. We need to look at what we can do from a healthcare industry and policy perspective to close this gap. Otherwise, we will be increasing disparities for the future.